Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
2. Ecolab
8.2% sales growth and 13.19% return on equity
Ecolab Inc. provides water, hygiene, and energy technologies and services worldwide.
Ecolab's sales growth this year is anticipated to be 6.1% and 6.6% for next year.
Year-on-year quarterly revenue growth declined by 5.5%, now sitting on 11.79B for the twelve trailing months.
Ecolab's sales growth for the next quarter is 8.2%. The company's growth estimates for the ongoing quarter and the next is 92.3% and 30.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.19%.
Volatility
Ecolab's last day, last week, and last month's current volatility was 3.85%, 1.75%, and 1.10%, respectively.
Ecolab's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.53% (day), 1.97% (last week), and 1.60% (last month), respectively.
Ecolab's Stock Yearly Top and Bottom Value
Ecolab's stock is valued at $222.07 at 23:22 EST, under its 52-week high of $231.36 and way above its 52-week low of $181.25.
Ecolab's Moving Average
Ecolab's worth is higher than its 50-day moving average of $216.28 and higher than its 200-day moving average of $212.63.3. OPKO Health
9.6% sales growth and 7.45% return on equity
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
OPKO Health's sales growth this year is expected to be 27.3% and a negative 20.1% for next year.
Year-on-year quarterly revenue growth grew by 157.8%, now sitting on 1.77B for the twelve trailing months.
OPKO Health's sales growth for the next quarter is 9.6%. The company's growth estimates for the ongoing quarter and the next is a negative 40% and negative -75%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.45%.
Volatility
OPKO Health's last day, last week, and last month's current volatility was 0.24%, 1.29%, and 2.09%, respectively.
OPKO Health's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.96% (day), 3.56% (last week), and 4.24% (last month), respectively.
OPKO Health's Stock Yearly Top and Bottom Value
OPKO Health's stock is valued at $4.10 at 23:22 EST, way below its 52-week high of $6.47 and way higher than its 52-week low of $1.91.
OPKO Health's Moving Average
OPKO Health's value is below its 50-day moving average of $4.38 and under its 200-day moving average of $4.45.4. Accenture plc.
15.4% sales growth and 31.88% return on equity
Accenture plc provides consulting, technology, and outsourcing services worldwide.
Accenture plc.'s sales growth this year is anticipated to be 10.9% and 7.5% for next year.
Year-on-year quarterly revenue growth grew by 8.5%, now sitting on 45.68B for the twelve trailing months.
Accenture plc.'s sales growth for the next quarter is 15.4%. The company's growth estimates for the ongoing quarter and the next is 17.9% and 2.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 31.88%.
Volatility
Accenture plc.'s last day, last week, and last month's current volatility was 0.89%, 0.54%, and 0.53%, respectively.
Accenture plc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.89% (day), 0.91% (last week), and 1.05% (last month), respectively.
Accenture plc.'s Stock Yearly Top and Bottom Value
Accenture plc.'s stock is valued at $291.73 at 23:22 EST, under its 52-week high of $293.42 and way above its 52-week low of $174.94.